MedTrace Logo

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

NCT02709096 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-09-14

Study results available
· View outcomes & findings →

Summary

This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BPX-01, 1% Topical Gel

topical gel, applied to the forehead, cheeks, nose and chin

DRUG

BPX-01 Vehicle Gel

topical gel, applied to the forehead, cheeks, nose and chin

Sponsors & Collaborators

  • BioPharmX, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart Lessin, MD · KGL, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709096 on ClinicalTrials.gov